• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      Lupin gets US FDA nod for anti-depressant

      Posted AtEconomictimes.indiatimes.com

      MUMBAI: Drug maker Lupin has received US Food and Drug Association (FDA) approval for anti-depressant, it said on Wednesday. Lupin can now make imipramine hydrochloride tablets of 10 mg, 25 mg and 50 mg strengths, as per the abbreviated new drug application (ANDA) approval, the company said. Shipments for the product are already on way, Nilesh Gupta, group president and executive director, told ET.

      The company estimates the market size for the product at $21 million (approximately Rs 95 crore) in the US. Lupin had filed 105 ANDAs as on December 31, 2009, and has received approval for 36.

      The approval marks the company’s fifth drug approval since January, when the FDA cleared its objections to Lupin’s Mandideep facility. While the curb on the Mandideep facility didn’t bar most of the product approvals Lupin has sought, there could have been a sentimental impact at the regulators end, analysts said.

      Indian pharmaceutical companies have been under heightened scrutiny lately, even as the Obama administration seeks to liberalise the use of generic drugs and lower costs of the country’s social security programme. Others like Ranbaxy and Sun Pharmaceutical’s US unit Caraco Pharmaceutical Laboratories continue to face warnings against manufacturing processes.

      March 22, 2010


       

      Share this Article!

    Back to top^